<DOC>
	<DOCNO>NCT00933426</DOCNO>
	<brief_summary>The goal Phase I part clinical research study find high tolerable dose Revlimid® ( lenalidomide ) give combination paclitaxel patient prostate cancer fail treatment taxanes . The goal Phase II part clinical research study learn lenalidomide paclitaxel help control prostate cancer . The safety combination treatment study phase study . UPDATE : Study terminate early due slow accrual Phase I dose escalation study , without progression Phase II study portion .</brief_summary>
	<brief_title>Lenalidomide Paclitaxel Prostate Cancer</brief_title>
	<detailed_description>Study Drugs : Lenalidomide drug change immune system may also interfere development tiny blood vessel help support tumor growth . Taking lenalidomide could prevent growth cancer cell . Paclitaxel design disrupt growth cancer cell , may cause cancer cell die . Phases I II : If find eligible take part study , assign study group base join study . Up 10 group 3 participant enrol Phase I portion study , 1 group 42 participant enrol Phase II . If enrolled Phase I portion , dose lenalidomide receive depend join study . The dose paclitaxel patient . Up 5 dose level lenalidomide test Phase I portion . The first group Phase I participants receive low dos lenalidomide . Each new group enrol receive high dos , intolerable side effect see . Groups continue enrol ( 10 ) high tolerable dose lenalidomide ( combination paclitaxel ) found . If enrol Phase II portion , receive lenalidomide high dose tolerate Phase I portion combination paclitaxel . Study Drug Administration : Once assign dose , take lenalidomide capsule mouth day 21 day row , follow 7 day rest ( Days 22-28 ) . This call `` lead-in '' period . '' You begin take lenalidomide paclitaxel 28 day study cycle . You take lenalidomide mouth every day Days 1-21 cycle . Paclitaxel give vein 1 hour Days 1 , 8 , 15 cycle . On Days 22-28 cycle , take study drug . The Day 1 dose Lenalidomide combination cycle may occur within +/- 5 day Day 1 paclitaxel dose . You swallow lenalidomide capsule whole water time day . Do break , chew , open capsule . If miss dose lenalidomide , take soon remember day . If miss take dose entire day , take regular dose next schedule day ( NOT take double regular dose make miss dose ) . If take prescribe dose lenalidomide seek emergency medical care , need , contact study staff right away . Females childbearing potential might care touch lenalidomide capsule bottle unless wear glove . In order participate study must also register follow requirement RevAssist® program Celgene Corporation . This program provide education counsel risk fetal exposure , blood clot , reduce blood count . You require receive counseling every 28 day treatment lenalidomide , follow birth control requirement program appropriate , take telephone survey compliance program . Study Visits : On Day 1 cycle ( receive paclitaxel ) , follow test procedure perform : - You physical exam , include measurement weight . - Your performance status record . - You ask drug treatment may receive . - Blood ( 2-3 teaspoon ) draw routine test test prostatic specific antigen ( PSA ) testosterone level . - You ask side effect may experience since last visit . On Days 8 15 cycle ( receive paclitaxel ) , follow test procedure perform : - Your weight measure . - Blood ( 2 teaspoon ) draw routine test . On Day 1 Cycle 3 every 2 cycle thereafter , follow test procedure perform : - You chest x-ray CT scan abdomen pelvis check status disease . - Blood ( 2 teaspoon ) draw test testosterone level liver function . - You bone scan check status disease . - You ECG . If treat paclitaxel local oncologist 's office , require return M. D. Anderson Days 1 15 Cycle 1 Day 1 cycle . All study visit may do local oncologist 's office . Length Study : You continue study long benefiting . You remove study experience intolerable side effect , disease get bad , study doctor think best interest . End-of-Study Visit : Once study , follow test procedure perform : - You physical exam . - Blood ( 3-4 teaspoon ) draw routine test test PSA testosterone level . - You ask side effect may experience since last visit . - Your performance status record . This investigational study . Lenalidomide approve Food Drug Administration ( FDA ) commercially available treatment specific type myelodysplastic syndrome ( MDS ) combination dexamethasone patient multiple myeloma ( MM ) receive least 1 prior therapy . Paclitaxel FDA-approved commercially available treatment bladder cancer , lung cancer , breast cancer , pancreatic cancer . The use drug combination investigational . Up 72 participant take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . Patients metastatic adenocarcinoma prostate 2 . Patients Phase II must radiographic evidence multiple ( &gt; /= 2 ) bulky ( &gt; /= 5cm diameter ) lymph node metastasis &lt; 2 bone ( radionuclide bone scan ) discrete sit involvement . 3 . Patient must frontline chemotherapy castrateresistant metastatic disease . Any number prior chemotherapy regimen permit , except within last 3 week . No prior thalidomide lenalidomide therapy permit . 4 . Patients must evidence progression disease base one follow criterion : ) PSA progression define 2 consecutive increment PSA ( absolute change least 1ng/mL ) 4 week . b ) An increase 25 % product bidimensional disease 30 % maximum diameter appearance unequivocally new lesion qualifies progression . c ) Worsening symptom clearly attributable disease progression qualify progression e.g . worsen malignant bony pain . 5 . Patients antiandrogens discontinue flutamide , nilutamide cyproterone acetate least 4 week bicalutamide 6 week . If progression document time interval , patient eligible . Patients response defer ( secondary ) therapy antiandrogens satisfy wait period prior enrollment . 6 . Patients must performance status &lt; /= 2 ( ECOG ) . 7 . Patients receive concurrent biological , immunological , secondline hormonal therapy chemotherapy . Patients receive replacement therapeutic dos corticosteroid nonmalignant disease disease progression establish may continue therapy . 8 . Patients must recover prior chemotherapy , biological immunological therapy radiation deliver within last 28 day . Radioisotope therapy strontium deliver within last 90 day samarium within last 60 day permit . 9 . Patients must castrate serum testosterone level ( &lt; /= 50ng/ml ) document last six week . For patient medically castrate , luteinizing hormone release hormone analog must continue maintain testicular suppression . 10 . Patients must adequate bone marrow function define absolute peripheral granulocyte count &gt; /= 1,500/mm^3 platelet count &gt; /= 75,000/mm^3 . 11 . Patients must adequate hepatic function define bilirubin &lt; /= 2 X upper limit normal AST/ALT &lt; /= 2.5 X upper limit normal . 12 . Patients must adequate renal function define creatinine clearance &gt; /= 40 cc/min ( measure calculate Cockcroft Gault formula ) . 13 . Must fully recover previous surgery , term wound heal . 14 . Patients must sign informed consent indicate aware investigational nature study , keep policy institution . 15 . All study participant must register mandatory RevAssist® program , willing able comply requirement RevAssist® . 16 . Men must agree use latex condom sexual contact female childbearing potential ( FCBP ) even successful vasectomy . A FCBP sexually mature woman : 1 ) undergone hysterectomy bilateral oophorectomy ; 2 ) naturally postmenopausal least 24 consecutive month ( i.e. , menses time precede 24 consecutive month ) . 17 . Patient must able take low molecular weight heparin ( prefer ) OR lowdose enteric aspirin warfarin thromboembolic prophylaxis . 1 . Patients severe uncontrolled infection define symptomatic and/or require intravenous antibiotic . 2 . Patients small cell sarcomatoid variant prostate cancer . 3 . Patients symptomatic congestive heart failure ( CHF ) , pulmonary embolus , vascular thrombosis , transient ischemic attack , cerebrovascular accident , unstable angina MI last 3 month evidence active myocardial ischemia symptom electrocardiogram ( ECG ) . 4 . Known severe hypersensitivity taxanes . 5 . Patients central nervous system ( CNS ) metastasis cord compression exclude except patient complete excision radiotherapy remain asymptomatic least 2 month . 6 . Oxygendependent lung disease &gt; /= grade 2 peripheral neuropathy . 7 . Known intolerance corticosteroid therapy would preclude use premedication paclitaxel . 8 . Uncontrolled severe hypertension uncontrolled diabetes mellitus . 9 . Active second malignancy . Nonthreatening second malignancy superficial lowgrade transitional cell carcinoma bladder Rai Stage 0 chronic lymphocytic leukemia stable small renal cell carcinoma may exempt stipulation discretion Principal Investigator . 10 . Overt psychosis mental disability otherwise incompetent give inform consent . Patients unwilling unable comply RevAssist® program history noncompliance medical regimen consider potentially unreliable . 11 . Patients know HIV active hepatitis A , B , C infection . 12 . Patients receive concurrent biological , immunological , secondline hormonal therapy chemotherapy . Patients receive replacement therapeutic dos corticosteroid nonmalignant disease disease progression establish may continue therapy . 13 . Patients recover prior chemotherapy , biological immunological therapy radiation deliver within last 28 day . Radioisotope therapy strontium deliver within last 90 day samarium within last 60 day permit .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Castration-Resistant Prostate Cancer</keyword>
	<keyword>CRPC</keyword>
	<keyword>Prostate</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Revlimid</keyword>
	<keyword>CC-5103</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Taxol</keyword>
	<keyword>Taxanes</keyword>
</DOC>